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Abstract 
 Approximately 15% of individuals infected with Human Immunodeficiency Virus 
(HIV) develop a neurological condition that consists of motor dysfunction and cognitive 
deterioration in late stage disease that is known as the AIDS dementia complex (ADC). 
This condition is mirrored in rhesus macaques infected with Simian Immunodeficiency 
Virus (SIV), which can be more easily studied. This project analyzed different 
macrophage populations in rhesus macaques infected and uninfected with SIV at early 
and terminal stage disease. Single and double immunohistochemistry stains were 
performed for the known macrophage and microglial markers CD163, CD16, CD68, 
Mac387, HAM56, and Iba-1, as well as for the SIV-p28 viral protein. Photographs and 
observations of the tissue stainings demonstrated that early after infection with SIV, there 
is an increase in perivascular macrophages and monocytes surrounding vessels and tissue 
edges, and the SIV-p28 protein is already present. There is also an observed change in the 
morphology of the microglia to an active, ramified state. After the development of AIDS 
and SIVE, the increase in all of the macrophage markers and the accumulation of 
activated microglia are clearly visible, especially surrounding and within lesions. 
Furthermore, these markers can be used to categorize the encephalitic lesions as “new” or 
“old” based on the presence or absence of Mac387 within the cells. All lesions contained 
CD68+ and HAM56+ macrophages, but “new” lesions presented with a relatively high 
count of Mac387+ macrophages that were newly imported from the periphery, whereas 
“old” lesions lacked Mac387+ cells. 
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Introduction  
Individuals with Human Immunodeficiency Virus (HIV) infection are predisposed 
to developing a large variety of opportunistic infections that undoubtedly result in 
immune activation, even in immunocompromised individuals. In addition to these 
secondary infections, approximately 15% of HIV-infected patients develop a neurological 
syndrome that consists primarily of motor dysfunction and cognitive deterioration 
(McArthur et al, 1993). Although neurologic complications can be drug-related, or the 
result of opportunistic infections and/or tumors, they can also be caused directly by the 
HIV virus. This primary infection by HIV can cause HIV encephalitis and a condition 
that is often referred to as the AIDS dementia complex (ADC) or HIV dementia (HIVD). 
This state is unique to HIV, and similar conditions are not seen in other 
immunodeficiency diseases. In many instances it is called “subcortical dementia” because 
memory impairment occurs after symptoms such as inattention, indifference, and 
psychomotor slowing (McArthur et al, 1994, Martin et al, 1992). This neurological 
infection is associated with HIV replication within the central nervous system (CNS) 
before the stage of immunodeficiency, and it results in the presence of HIV-specific 
antibodies, which may be regarded as evidence of active infection of the brain. This 
dynamic infection by HIV has been confirmed by studies that have demonstrated the 
presence of HIV-infected cells in both the brain and spinal cord (Gonzalez-Scarano and 
Baltuch, 1999). HIVD can be distinguished from almost all other nervous system viral 
diseases because there is significant cognitive and motor slowing, but no direct infection 
of neurons. Instead, HIV is primarily concentrated in brain macrophages, microglia, and 
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perivascular macrophages. Infection is rarely seen in astrocytes, endothelial cells, and 
neurons (Wiley et al 1986, Gabuzda et al 1986). 
 The mechanism by which HIV leads to HIVD is currently under intense research. 
Since it is often difficult to study the neurological effects of HIV in the human brain until 
post mortem, most research regarding mechanisms of pathogenesis is performed in 
macaque models infected with simian immunodeficiency virus (SIV), a closely related 
lentivirus to HIV (Desrosiers 1990, Lackner 1994). Simian immunodeficiency viruses 
have similar sequence homology, genomic organization, and biological properties to both 
HIV strains, HIV-1 and HIV-2. Like HIV-1, the target cells of SIV are lymphocytes, 
macrophages, and monocytes (Desrosiers et al. 1991, Hurtel et al. 1993). Comparable to 
human immunodeficiency virus infection, approximately 30-40% of SIV-infected 
monkeys develop encephalitis, mental deterioration, and CNS lesions (Lackner et al. 
1991). In fact, it is generally accepted that HIV evolved from transmission events that 
occurred cross-species from African primates to humans (Marx et al. 1991).  
 Understanding how HIV and SIV traffics throughout the body is the key to 
discovering how HIVD progresses. It is evident that HIV replication occurs at a high 
level throughout infection. Generally, the host mounts a robust but ineffectual adaptive 
immune response to initial infection that includes antibody and cellular responses (Picker 
& Watkins 2005). Both HIV and SIV utilize the CD4 cellular receptor, a membrane 
glycoprotein, along with an additional chemokine receptor such as CCR5 or CXCR4, to 
attach to T cells in initial infection (Choe et al, 1996). Global immune deficiency is the 
result of the direct infection of these CD4+ helper T cells, since their subsequent 
destruction leaves the body unable to control basic immunological functions (Alkhatib et 
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al. 1996). Infection of monocytes and macrophage cells is also significant in the 
progression of the virus and chronic infection. It has been shown that these cells are 
likely to be the primary reservoirs for viral replication and persistence, as they are long 
lived, often sequestered from antiretroviral drugs, and can harbor virus for years. It is also 
possible that they contribute to immune deficiency. Macrophages are not only important 
in the evolution of the neurological disorder of HIVD, but they may also contribute to 
AIDS-related syndromes in nonlymphoid organs, such as the heart and kidneys (Ross and 
Klotman 2004, Shannon 2001). If left untreated, viral replication continues at high levels, 
and the number of CD4+ T cells progressively decreases, leading to the emergence of 
AIDS (Picker and Watkins 2005). 
Although it is known how HIV infects the adaptive immune system and 
macrophage populations, many HIVD researchers are interested in how the virus is able 
to infect the cells of the brain. Of particular interest are the CNS perivascular cells. 
Perivascular cells are found within the CNS in the perivascular space, also known as the 
Virchow-Robin space (Peters et al., 1976). There are several types of perivascular cells, 
including perivascular microglia, fluorescent granular perithelial cells, and perivascular 
macrophages. This relatively minor population of cells in the CNS is situated adjacent to 
endothelial cells just beyond the membrane of blood vessels. Perivascular macrophages 
are seen to wrap around CNS vessels, and they combine with astrocytes to form the 
majority of the blood-brain barrier. Microglial cells also comprise part of this barrier, 
approximately 5-13% (Hickey et al., 1992, Lassman et al., 1993). Perivascular 
macrophages are derived from the bone marrow and are continuously replaced by 
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monocytes at a steady rate in a normal, noninflamed brain (Lassmann et al., 1986, Hickey 
and Kimura, 1988, Soulas et al., 2009).  
Studies have implicated perivascular cells in transient CNS inflammation where 
cells of the peripheral immune system infiltrate the CNS (Williams et al, 2001). Further, 
perivascular macrophages become activated in response to neuronal injury or death 
(Streit and Graeber, 1993). In addition, perivascular cells may phagocytose and 
pinocytose foreign agents and debris and respond to cytokines (Kida et al., 1993). In this 
way, it is possible that perivascular cells may transport CNS antigens to the immune 
system, or they may transmit responses of peripheral immune activation to the CNS 
(Elmquiest et al., 1997). In cases of neuronal injury or brain inflammation, perivascular 
macrophages are capable of recruiting more monocytes to the site of injury. This 
monocyte trafficking process is dynamic: as perivascular macrophages accumulate, 
chemokines and colony-stimulating factors (CSF) are produced, which may serve as 
attractants for additional cells entering the CNS (Kim et al, 2003). These chemokines, for 
example IL-1 and IL-6, are not only important in subsequent macrophage activation, but 
may also result in the prolonged survival of the perivascular macrophage cells (Berman et 
al., 1994).  
In instances of severe trauma, such as when a foreign body is present or an 
intracellular pathogen can not be destroyed, highly activated macrophages might fuse 
together, forming multinucleated giant cells (MNGCs). The presence of MNGCs is a 
diagnostic hallmark of HIVE/SIVE, and these cells are rarely found in other types of 
CNS disease (Budka 1986). Taking all of these observations into account indicates that 
the perivascular cells have important immunological surveillance functions within the 
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brain. They take up foreign CNS antigens through phagocytosis and present them to 
blood macrophages, as well as recruiting more macrophages. They are able to sense 
neuronal injury or death. They also sense peripheral nervous system (PNS) injury and are 
sensitive to cytokine levels outside of the CNS. Although the brain is considered 
immunologically privileged, it is important for the CNS to have some means of 
communication with the periphery, which is accomplished through the signals produced 
by perivascular cells.  
Because of their unique position within the brain, their short half-life and 
relatively high turnover rate, perivascular macrophage cells are considered likely targets 
of SIV/HIV infection (Williams et al., 2001a). Scattered HIV- or SIV- infected 
macrophages that are viral DNA, RNA, and protein positive are consistently found during 
the peak viremia stage of disease, or approximately 7-14 days post-infection (Kim et al. 
2003). They are thus suggested to function as “Trojan horse” cells responsible for 
carrying virus to the CNS and are targets of productive infection within the brain. It is 
believed that lentiviruses such as HIV enter the CNS through the trafficking of infected 
macrophages or monocytes (Peluso et al., 1985). The original infected macrophages enter 
the brain early after infection and accumulate around perivascular cuffs (Lane et al., 
1996). During the asymptomatic phase of HIV, productive infection of virus is not 
detectable (Gosztonyi et al., 1994, Williams et al., 2001a). The development of full-
blown AIDS leads to the productive infection of the virus within these cells. It is 
plausible that this is the result of the original infected CNS perivascular cells either dying 
or exiting the brain and being replaced with uninfected perivascular cells during the 
asymptomatic stage of HIV infection when the virus is still under control by the CD4+ T 
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cells of the peripheral immune system. Productive infection occurs from the reseeding of 
new virus from the periphery as CD4+ T-cells are killed due to viral infection (Clements 
et al., 2002).  
Microglia are another type of CNS cell that have been implicated in the 
progression of HIV/SIV CNS disease and other degenerative CNS conditions. Microglia 
are considered the principal immune cells within the CNS, and they have a critical role in 
defense against invading microorganisms. Microglia compose approximately 10% of the 
glial cell population of the adult CNS (Vaughn and Peters, 1974). They have been 
separated into two primary subtypes based on their location and morphology. 
Parenchymal microglia originate from monocytes that migrate into the CNS early in 
development. There, they make up a pool of cells with a low turnover rate and very 
limited replication (Richardson et al., 1993). Generally located closely to neurons within 
the grey matter of the brain, parenchymal microglial cells are characterized by an 
elongated soma with processes extending from both poles of the cell body (Lawson et al., 
1990).  Another, specialized type of microglia have close contact with the blood vessels 
in the brain and are categorized as perivascular microglia (Graeber et al., 1989). These 
cells have a higher turnover rate, and they are regularly replenished by monocytes from 
the periphery. It is possible that a perivascular microglia penetrate the CNS and 
differentiate into a parenchymal microglia, but this occurs only rarely (Gonzalez-Scarano 
and Baltuch, 1999).  
Microglia rapidly respond to different forms of CNS injury. They alter their 
morphology by retracting their processes and rounding their cell body. They proliferate 
and upregulate certain surface molecules, such as MHC class I and II molecules that 
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enable microglia to interact directly with T cells (Hickey and Kimura, 1988). They also 
become phagocytic and release inflammatory cytokines that serve to amplify the 
inflammatory response at the site of injury (Gonzalez-Scarano and Baltuch, 1999). 
Similar to macrophages, microglia release a variety of potentially harmful factors into the 
brain along with the proinflammatory cytokines. These include reactive oxygen and 
nitrogen intermediates, proteolytic enzymes, arachidonic acid metabolites, and potentially 
cytotoxic cytokines like tumor necrosis factor alpha (TNFα) (Banati et al, 1993, Renno et 
al., 1995, Kreutzberg, 1996). These inflammatory responses are characteristic of several 
chronic CNS diseases, including AIDS.  
 In HIVD, the presence of HIV-infected microglia, as well as macrophages, is 
important. HIV-infected microglia can be detected by their expression of HIV antigens, 
specifically against gp41, the viral transmembrane glycoprotein. It is interesting to note 
that HIV infection of microglia occurs in nearly all patients, however, not all patients will 
develop dementia due to the presence of the virus. From this observation it has been 
concluded that viral replication alone is insufficient to cause clinical disease until other 
factors amplify the effect of the HIV infection (Gonzalez-Scarano and Baltuch, 1999). 
Although parenchymal microglia are not the first cells to become infected by the virus, 
they play an important role in viral persistence. Infected microglia may survive for 
relatively long periods within the brain, which enables them to produce significant 
amounts of virus to maintain cycles of infection creating a reservoir of infection within 
the CNS.  
It is evident that both macrophages and microglia in the CNS secrete products that 
ultimately are the cause of neural degeneration in HIVD; therefore, these cells not only 
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act as carriers of the virus or sites of active viral replication, but as mediators for further 
CNS injury. Once a neuron’s function has been compromised, it may further participate 
in recruiting macrophages to the CNS by the secretion of fractalkine, which modulates 
the secretion of TNFα and contributes to a cycle of increasing neuron damage (Tong et 
al, 2000). Identification of these candidate neurotoxins has been approached through 
analysis of their effects on neuronal death or injury in culture systems (Tardieu and 
Janabi, 1994). HIV-infected microglia secrete viral surface glycoproteins such as gp120. 
Gp120 is a glycoprotein expressed on the HIV envelope that is crucial for viral entry into 
cells (Zhou et al, 2007). They also secrete other viral proteins like tat, which activates the 
viral promoter, and nef, a regulatory protein. Many studies have focused on gp120 and its 
effects on neuron viability. In most of these studies, neurotoxicity has been attributed to 
glutamate-receptor mediated cell death, possibly due to activation of NMDA receptors 
that leads to a deadly calcium influx (Lipton 1996). The viral protein tat, although shown 
to have neurotoxic activity (Sabatier et al, 1991, Kolson et al, 1993), has not been 
sufficiently studied, and the mechanism of its activity is not known. 
Of even greater concern to neurons are endogenous microglial and macrophage 
secretory products such as TNFα, cytokines, chemokines, arachindonic acid, and nitric 
oxide. TNFα is released by HIV-infected microglia, and it has been seen that levels of 
TNFα mRNA are higher in the subcortical regions of the CNS in patients who exhibit 
HIVD than in HIV-infection patients who do not (Wesselingh et al, 1997). Arachindonic 
acid is a product of macrophages within the CNS, and it potentiates NMDA receptor 
currents in neurons, again resulting in the accumulation of calcium that causes neuronal 
death (Demuis et al, 1995). Nitric oxide has also been proposed to be a potential mediator 
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for neuronal toxicity in numerous neurological diseases and may contribute to microglial 
injury (Adamson et al, 1996). Quinolinic acid, a metabolite of tryptophan, may also act as 
an NMDA receptor agonist to induce neuron death (Brew et al, 1995). It is known to be 
produced by macrophages, and it may be one of the more important neurotoxins in 
HIVD. As previously stated, other cytokines including IL-1, IL-6, TGFβ, and platelet 
activating factor (PAF) are secreted by activated CNS cells (Gonzalez-Scarano et al, 
1999), but to what extent these cytokines can induce neuronal damage at the 
concentrations they are produced within the CNS is still unanswered.  
Because of their substantial role in trafficking HIV into the CNS, it is important to 
look at the types of macrophage populations in CNS lesions and their stage of 
development. It is also significant to observe how the microglial cell populations may 
vary during different stages of disease, since these cells have been shown to be 
significant in the development of HIVD as well. In order to visualize the different stages 
of macrophage development within the CNS, specifically in areas including CNS lesions 
due to HIV/SIV, various molecular markers and immunohistochemistry procedures can 
be used. In addition to looking at these macrophage markers, an anti-SIV p28 molecule 
can be used to visualize the location of the SIV protein within the tissue and serve as a 
marker of productively infected cells. 
For example, CD163 is a membrane glycoprotein that belongs to the scavenger 
receptor cystein-rich (SRCR) superfamily group B (Kristiansen et al., 2001), and it is 
involved in a signal transduction pathway that results in the production of various 
cytokines (Ritter et al., 2001). The protein is exclusively expressed on all circulating 
monocytes and on subpopulations of tissue macrophages. It mediates removal of 
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hemoglobin-heptagloben complexes, and inflammation is regulated by the protein in its 
soluble form (Kristensen et al, 2001). It has been shown that CD163 is specifically 
expressed by perivascular macrophage in the normal CNS, and these cells are located 
within the Virchow-Robin space and outside of the vascular basement membrane. 
(Fabriek et al., 2005). Further studies have shown that CD163 is primarily confined to 
perivascular macrophages in brains of monkeys or humans with SIV and HIV. CD163+ 
cells were mainly found in association with CNS vessels that were positive for Glut-1, a 
glucose transporter that is found in CNS microvessels. Scattered microglia in SIV 
encephalitis lesions and MNGCs were also found to be CD163+. All SIV-infected cells 
within the brains of monkey subjects are CD163+, which is consistent with the findings 
that perivascular macrophages are primary targets of SIV and HIV, however, not all 
CD163+ cells were shown to be SIV-infected. In HIVE and SIVE brains, perivascular 
CD163 expression is upregulated, and the number of CD163+ cells, including MNGCs is 
increased (Kim et al., 2006). As the disease progresses, CD163 is found to be expressed 
by microglia. In these later stages of encephalitis, the activated microglia that were 
CD163+ were consistently found to be located near a SIVE lesion (Roberts et al., 2004). 
It has been suggested that damage to the blood-brain barrier and subsequent immune 
activation could result in this localized expression of CD163 on microglial cells (Borda et 
al., 2008). 
Monocytes and macrophages are also CD16+, and CD16+ monocytes may play 
an important role in HIV pathogenesis. CD16 is a multifunctional Fc receptor for IgG 
molecules, and it is involved in phagocytosis, enzyme secretion, release of mediators of 
inflammation, antibody-dependent cellular cytotoxicity, and clearance of immune 
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complexes (Van de Winkel & Anderson, 1991). Specifically, CD16A is expressed by 
many immune cells, including mast cells, a subset of T lymphocytes, NK cells, 
monocytes, and macrophages. CD16+ monocytes are a minor subset of monocytes, and 
they contribute to approximately 5-15% of a healthy individual’s peripheral blood 
monocytes. This proportion increases in numerous inflammatory conditions, including 
HIV-1 infection (Thieblemont et al., 1995). The majority of monocytes in the peripheral 
blood are phenotypically CD14+/CD16-. This primary population of monocytes secretes 
less proinflammatory cytokines and neurotoxic factors compared to the CD16+ 
monocytes. In addition, CD16+ monocytes have lower phagocytic and oxidative activity, 
exhibit a macrophage-like morphology, and have more efficient antigen presentation 
functioning (Ziegler-Heitbrock et al., 1993). As well as being expressed on cell surfaces, 
CD16 may also be found in a soluble form detected in saliva, synovial, seminal fluid, and 
serum (de Haas et al., 1994), and which augments in disease states including HIV 
infection (Khayat et al., 1990). In patients with ADC, CD16+ monocytes are amplified in 
blood and are accumulated in perivascular sites within the brain (Fischer-Smith et al., 
2001). Furthermore, the CD16+ monocyte population has an increased susceptibility to 
HIV infection (Crowe et al., 2003) and may contribute to maintaining tissue macrophage 
reservoirs of HIV (Orenstein et al., 1997).  
Mac387 is a marker for macrophages, specifically newly-blood derived 
macrophages that have just entered a tissue. This molecule is expressed at early stages of 
monocyte/macrophage differentiation and can consequently be used as a marker for 
newly imported macrophages to the brain, differentiating from resident brain 
macrophages. It has been shown that Mac387+ macrophages accumulate around lesions 
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in SIV-infected monkeys, yet SIV+ cells do not express Mac387. In humans with HIV 
encephalitis, Mac387+ macrophages are also found to be accumulated in the vicinity of 
lesions. Mac387 is also occasionally expressed by circulating CD16+ monocytes, as well 
as tissue-infiltrated CD16+ monocytes. Although situated around CNS lesions, Mac387+ 
cells can not be considered reservoirs for productive infection because of their 
differentiation stage, yet they can serve as indicators of CNS disease. It is possible that 
they are SIV and HIV DNA+, but are not productively infected with the SIV or HIV 
RNA and protein. 
HAM56 and CD68 are macrophage markers for late stage resident macrophages 
developmentally. Similar to Mac387+ macrophages, HAM56+ and CD68+ macrophages 
amass within and around SIV/HIV lesions. CD68 is a transmembrane glycoprotein that 
can be used as a marker for monocytes and tissue macrophages. Produced throughout 
monocyte differentiation, it has a stronger intensity in macrophage than monocytes 
(Oehmichen et al., 2008).  HAM56 is used as a specific marker for tissue macrophages. It 
is an antibody that is reactive with macrophages, although the antigen is not yet known. 
After brain injury or trauma, both CD68+ and HAM56+ macrophages within the CNS are 
upregulated (Engel et al., 1996). 
A marker often used for microglia is the actin-binding protein known as ionized 
calcium-binding adapter molecule-1 (Iba-1) (Ahmed et al., 2007). Many 
immunohistochemical studies have used Iba-1 as a marker for microglia, mainly in non-
human animal tissue. Recent studies have shown that Iba-1 can be used in human tissue 
samples and can serve as a marker for both ramified and amoeboid microglia, and its 
epitopes are also stable over time (Ahmed et al., 2007). As previously stated, when 
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microglia become activated, they undergo dramatic changes in morphology, proliferation, 
migration, and phagocytosis, all of which are related to rearrangements of the actin 
cytoskeleton. Iba-1 has been shown to colocalize with F-actin and to be crucial to 
membrane ruffling events following secretion of macrophage colony-stimulating factor 
and phagocytosis in cultured cells (Ohsawa et al., 2000). More recently, Iba-1 has been 
found to play a role in regulation of the rearrangement of the actin cytoskeleton (Ohsawa 
et al., 2004). After brain injury, microglia become triggered, and is has been 
demonstrated that Iba-1 expression is upregulated specifically in these activated cells (Ito 
et al., 2001).  
The goal of this study was to use these various macrophage and microglial 
markers to observe brain sections of rhesus macaques during early stage disease and after 
developing SIVE and AIDS. Through the use of immunohistochemistry, this experiment 
aimed to determine when and where the various populations of macrophages are located 
within the brain or encephalitic lesions during the progression of the disease. 
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Materials & Methods 
 
Tissue Samples 
In this study, tissues from 7 juvenile rhesus macaques (Macaca mulatta) were 
observed. All animals used in this study were CD8 depleted for rapid consistent AIDS 
with a high incidence of SIVE (>90%). The animals were administered 10 mg/kg of anti-
CD8 Ab cM-T807 subcutaneously on day 6, and intravenous 5 mg/kg administrations on 
days 8 and 12 of infection. Four of the 7 animals (A98-41, A97-596, A98-182, A00-360) 
were infected intravenously with SIVmac251 (20 ng of SIV p27), and were sacrificed 
after developing SIVE and terminal AIDS. Euthanasia was performed when the animals 
developed AIDS, based on several criteria including weight loss of >15% in 2 weeks or 
>30% in 2 months, documented opportunistic infection, persistent anorexia lasting 
greater than 3 days without explicable cause, severe diarrhea, progressive neurologic 
signs, significant cardio and/or pulmonary signs, and any other serious illnesses. 2 
animals (A01-250 and A01-256) were infected with SIVmac239, and killed at 20 days 
and 23 days post infection, respectively. These animals were SIV infected and sacrificed 
with early disease. The remaining animal A08-257 was an uninfected control. All animals 
were anesthetized with ketamine-HCl and euthanized by intravenous sodium 
pentobarbital according to AVMA guidelines. CNS tissues were collected in 10% neutral 
buffered formalin and embedded in paraffin. They were then sectioned at 5 µm. 
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Immunohistochemistry 
 Before beginning the immunohistochemistry staining, a Hemotoxylin and Eosin 
(H&E) Stain was performed on numerous tissue sections in order to determine which 
sections would be the best candidates for this study. This was done by rehydrating the 
paraffin sectioned slides, counterstaining with Harris Hematoxylin for four minutes, and 
then rinsing with running water. The slides were then dipped sequentially in acid alcohol, 
ammonia water, 80% alcohol, and eosin, and then dehydrated and mounted. This stain 
allowed for visualization of cellular morphology in the paraffin sections, so sections with 
sufficient lesions due to SIVE could be chosen. 
From the H&E staining results, several tissue samples were chosen from each 
animal based on the presence of SIV lesions within the tissue. Deparaffinized tissue 
sections were then assessed for the presence of various cell-surface markers by 
performing numerous single and double immunohistochemistry stains. The antibodies 
used can be seen in Table 1. Single immunohistochemistry was performed using 
antibodies to CD16, CD163, CD68, Mac387, Iba-1, HAM56, and SIV protein P28. 
Antigen retrieval was performed for each procedure since the formalin fixation of the 
tissue sections leads to a reduction in the affinity for the antibody and it is necessary to 
restore the antigen’s optimal immune reactivity. Antigen retrieval was done using 
primarily a citrate concentration of 1:200. The exception to this was the stain for 
HAM56, which utilized a Proteinase K (DAKO) antigen retrieval system. The slides were 
then treated with a peroxidase block (DAKO) for 5 minutes. The peroxidase block was 
performed in order to prevent non-specific background staining of the HRP to 
endogenous peroxidases that may be found within the tissue. This was followed by a 
 19
protein block (serum free) (DAKO) to further suppress unspecific binding for 20 minutes 
at room temperature. The primary antibody was then prepared at the recommended 
dilution using an Antibody Diluent with background reducing component (DAKO), and 
was added to the slides and left for one hour at room temperature in the dark. A 
polymer/HRP was then added with an incubation time of 30 minutes. The color reaction 
product was developed using 3,3’-diaminobenzidine tetrahyrochloride (DAB; DAKO) as 
the chromogenic substrate. The sections were counterstained with hematoxylin, 
dehydrated, and mounted. 
 In order to see if the markers were coexpressed on the tissue cells, several double 
stains were also performed using the DAKO Double Stain System. These stains included 
Glut-1/CD163, Glut-1/Mac387, CD68 (biotin)/Mac387, HAM56/CD68, 
HAM56/Mac387, and Glut-1/Iba1. The same procedure was followed as for single stains, 
using DAB as the first chromogen. Development was followed by the application of a 
doublestain block, followed by addition of the second antibody which was prepared 
according to the recommended dilution in an antibody diluent with background reducing 
component (DAKO). A linker was applied for 15 minutes at room temperature, followed 
by a polymer/AP for 30 minutes. The second antibody stain was developed using Vector 
Blue (Vector Laboratories). The slides were then dehydrated and mounted. 
 
Photography 
 Photos were then taken at a magnification of either 100X or 200X on a Zeiss 
Axiocam MR confocal microscope. 
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Table 1: Antibodies used in this study (N/A: Not Applicable) 
Antigen Clone Isotype Manufacturer Dilution (µL) 
CD16 2H7 Ms IgG2a Novocastra 1:20 
CD68 (biotin) KP1 Ms IgG1 ThermoScientific 1:400 
CD68 KP1 Ms IgG1 DAKO 1:400 
CD163 10D6 Ms IgG1 Novocastra 1:250 
Mac387 Mac387 Ms IgG1 DAKO 1:100 
Iba-1 N/A Rb polyclonal Wako 1:500 
Glut-1 N/A Rb polyclonal Chemicon 1:1000 
HAM56 HAM56 Ms IgM DAKO 1:50 
P28 3F7 Ms IgG1 Bartels 1:500 
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Results 
 The control animal A08-257 showed minimal CD16+ cells in the brain tissue. 
These cells were located around meningeal areas, but lacked any focal point (Figure 1c). 
A baseline level of CD163+ cells was also seen in these areas (Figure 1b), but CD16+ 
and CD163+ cells were not observed in the rest of the brain tissue. CD68+ cells were 
sparingly scattered throughout the brain matter, also without a focal region (Figure 1e). 
No significant SIV-p28, Mac387, or HAM56 positive cells were observed in the tissues 
(Figure 1a, d, e). A baseline, normal level of Iba-1 positive microglia can also be seen in 
the tissue (Figure 1g). 
 The animals A01-250 and A01-256 showed an increase in the majority of the cell 
markers in this study. SIV-p28 was visible in a few scattered cells in meningeal and 
perivascular spaces (Figures 2a & 3a), but no lesions were present in tissues observed 
from these two animals. Although not observed in most of the brain matter, the amount of 
CD16+ cells in the meninges increased compared to the control, showing early meningeal 
inflammation. CD16+ cells were also visible in perivascular areas (Figures 2c, 3c). 
Additionally, the CD163 cellular marker was increased in both the meningeal regions and 
perivascular areas (Figures 2b, 3b), yet like CD16, no cells within the brain matter were 
stained positive. This is consistent with perivascular inflammation and accumulation of 
monocytes and macrophages. Mac387 could be seen in extremely small quantities around 
vessels (Figures 2d, 3d). Staining for CD68+ cells showed an increased number of 
positive cells in the meninges (Figure 2f), a small congregation of cells around 
perivascular spaces (Figure 2g), and a scattered number of positive cells in the remaining 
tissue areas (Figure 3f). Very little to no HAM56 positive cells were observed in these 
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tissues (Figures 2e, 3e). A substantial increase in Iba-1+ microglia was observed as well 
as the change in morphology of the microglia that is visible at this stage of disease 
(Figure 2g). 
 The four animals that were sacrificed after developing AIDS and SIVE showed 
substantial increases in the markers studied, although different lesions showed different 
concentrations of cells with these markers present, and the markers in the various tissues 
studied stained with different intensities.  One focal lesion of animal A97-596 temporal 
and hippocampus tissue showed an increase in the SIV-p28 marker for SIV (Figure 4a) 
compared to both the control and the more recently infected samples. An increase in 
CD163+ cells was also seen directly adjacent to blood vessels as well as in the rest of the 
lesion (Figure 4b). CD16 staining was very light compared with other lesions observed in 
the same animal, but a higher intensity was observed around perivascular regions of the 
lesion (Figure 4c). Numerous cells in the lesion were HAM56+ (Figure 4e) and CD68+ 
(Figure 4f). The CD68 staining was particularly intense in this lesion, and a majority of 
the cells were positive. Mac387+ cells were less prevalent in this lesion. Mac387 is very 
weak, and only a few positive cells can be visualized (Figure 4d). The double stain for 
HAM56 and Mac387 in this lesion confirms the weak presence of the Mac387 marker as 
compared to HAM56 (Figure 4h). It is also clear that many of the cells within the lesion 
are positive for Iba-1 (Figure 4g), demonstrating the congregation and activation of the 
resident microglia to the virus. 
 Animal A98-41 also presented with significant SIVE lesions. In the cerebrum, 
one particular lesion was photographed. This lesion also showed a substantial amount of 
SIV-p28 positive cells (Figure 5a). The CD163 stain on the tissue was very strong, with 
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almost all of the cells within the lesion appearing positive, as well as many cells in the 
surrounding tissue (Figure 5b). A significant presence of CD16+ cells was also seen, and 
the stain is stronger in this lesion than in the lesion observed in the tissue of A97-596 
(Figure 5c). A Mac387 stain for this lesion showed some positive macrophage present 
within the lesion (Figure 5d), but the Mac387+ cells appear to be more spread out and 
fewer in number than the other macrophage populations, consistent with the idea that 
they are just differentiating from monocytes. The CD68 stain showed the greatest 
intensity and it is clear that almost all of the cells within the lesion are CD68+ (Figure 
5f). CD68+ cells were also seen outside of the lesion in the surrounding tissue, as well as 
in numerous smaller lesions and perivascular regions throughout (Figure 6a). HAM56+ 
cells were also observed in this lesion, primarily located in the center areas (Figure 5e). A 
double stain for HAM56 and CD68 shows the coexpression of the two molecules in a 
different lesion of the tissue (Figure 6b), though not all of the cells had both markers 
expressed. The stain for Iba-1 resulted in a highly visible positive cellular population 
within the lesion, almost 100% of the cells (Figure 5g). Additionally, many Iba-1+ cells 
can be seen in the tissue adjacent to the lesion. 
 Also observed from A98-41 were several lesions in the hippocampus. These 
lesions were significantly smaller in size, but were close together in the tissue. As in the 
other SIVE lesions, they displayed positive markers for SIV-p28 (Figure 7a, b). The 
lesions also were positive for CD163 (Figure 7c, d). As seen in the cerebrum, numerous 
cells outside of the lesions in the surrounding tissue also are positive for the marker. 
Similar results were seen for the CD16 marker (Figure 7e, f). Staining for Mac387 within 
these lesions showed some positive cells in the region, but only in two of the lesions. The 
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third, smallest lesion had no positive macrophages present (Figure 7g, h). The results 
from the HAM56 stain showed that the lesion lacking Mac387+ cells had a significant 
accumulation of HAM56+ macrophages (Figure 8a), and HAM56 also had presence in 
surrounding tissue and lesions (Figure 8b).  CD68+ cells were intensely stained in all 
three lesions (Figure 8c, d). As previously seen, some of the surrounding tissue cells were 
phenotypically CD68+, but to a lesser extent than the CD163+ cells. The HAM56/CD68 
double stain again showed the coexpression of the two markers on macrophages in 
observed encephalitic lesions (Figure 8h). The double stain for CD68/Mac387 was 
somewhat difficult to read because of the very small amount of Mac387 that is present 
within SIV lesions (Figure 8g). Since they are newly differentiated and imported 
macrophages, only a few Mac387+ cells were present and there was a strong presence of 
CD68+ resident macrophages, so it was hard to determine whether the two molecules 
were coexpressed within the lesions. It is likely that the two molecules are not 
coexpressed since they are markers for macrophages in different stages in development. 
As in the other SIV lesions, an increase can be seen in Iba-1+ cells, although the 
percentage of the cells in the three different lesions varies. The largest lesion has a high 
percentage of Iba-1+ cells (Figure 8f), but the other two lesions have a less defined 
population (Figure 8e).  
 A focal lesion in animal A00-360 was also looked at. This lesion was located in 
the occipital cortex and was substantial in size. Although the lesion itself was large, the 
SIV-p28 stain indicated that only about half of the cells within the lesion were SIV-p28+ 
(Figure 9a). The CD163 stain showed a number of cells positive for the marker, but 
compared to the previously observed lesions in animals A98-41 and A97-596, the stain is 
 25
very light (Figure 9b). It is clear that there is a focus of CD163+ cells within the lesion, 
but the number of these cells is significantly less. CD16+ cells were comparable in 
intensity and number to the other lesions observed (Figure 9c).  Mac387+ cells were 
present in this lesion as well (Figure 9d). HAM56+ macrophages were also visible within 
the lesion (Figure 9e), and these cells were more focused in the center of the lesion 
compared to the Mac387+ cells, which were more spread out. Almost all of the center 
cells in the lesion are HAM56+. CD68+ cells are also clearly visible within the lesion, 
and these cells are primarily concentrated in the center regions as well (Figure 9f). The 
presence of HAM56 and Mac387 macrophages can be seen to both be present within the 
lesion in the double stain, but they do not appear to be coexpressed (Figure 9h).  The Iba-
1 stain also shows a high percentage of positive cells in the lesion and the surrounding 
tissue (Figure 9g). 
 The results of these stains are summarized in Table 2 below. 
Animal P28 CD163 CD16 Mac387 HAM56 Iba-1 CD68 
A08-257 - +/- +/- - - + + 
A01-256 + + + +/- - ++ + 
A01-250 + + + + - ++ + 
A97-596 +++ ++ ++ - ++ +++ ++ 
A98-41 (1) +++ +++ +++ + ++ +++ +++ 
A98-41 (2) +++ +++ +++ +/- +/+++/- ++/+++ +++ 
A00-360 ++ ++ ++ + ++ +++ +++ 
Table2: Amounts of positive cells for various cellular markers within brain tissue or 
lesion. (- indicates no visible positive cells, + indicates <20%, ++ indicates 20%-60%, 
+++ indicates >60%. A +/- indicates that some regions were positive and others were 
not.) 
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Discussion 
 The purpose of this project was to observe and attempt to quantify macrophage 
populations surrounding CNS lesions in rhesus monkeys exhibiting SIVE, while 
simultaneously learning immunohistochemistry techniques.  
 The tissue stains from the control animal, A08-257, demonstrated that 
macrophage markers CD163 and CD16 are present within normal brain tissue, but 
majorly confined to vessel regions or the edges of tissue. This is consistent with the belief 
that CD163 is considered primarily a perivascular macrophage marker, and CD16 is 
found on small population of monocytes within the individual’s blood. It is clear that the 
population of macrophages with these markers is very small in an uninfected brain. No 
Mac387 was observed in the normal brain tissue. Since Mac387 is generally considered 
to be a marker of new macrophages, this indicates that no new macrophages are being 
imported into the brain. The baseline presence of CD68+ cells within the brain tissue can 
be attributed to resident macrophages that may have crossed the blood-brain barrier at 
some earlier stage. The control tissue stained also showed numerous Iba-1+ cells, spread 
evenly throughout the tissue. These are the native microglial cells, and they have an 
amoeboid appearance, demonstrating that they are in a “resting” state. 
 When the control tissue stains are compared with the newly infected macaques, 
A01-250 and A01-256, some changes are very easy to observe. For example, the increase 
in perivascular macrophages (CD163+) and monocytes (CD16+) surrounding the vessels 
and tissue edges is unmistakable. There is already a presence of the SIV protein p28, 
primarily in these same vessel areas. The baseline level of CD68+ cells in the tissue 
appears to be the same as in the control animal, yet there is an accumulation of CD68+ 
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cells around the blood vessels that was not observed in control tissues. This could be due 
to a recruitment of existing macrophages or monocytes from the blood to fight the initial 
viral infection. The presence of a few Mac387+ macrophages, also close to blood vessels, 
is indicative of the start of macrophage trafficking in response to the infection. Since the 
disease at this stage (2-3 weeks post infection) is still under control by the adaptive 
immune system, no significant introduction of macrophages into the brain is expected. 
The most drastic change at this stage in disease is the increase and change in morphology 
of microglia. The Iba-1 staining clearly shows that the microglia have become more 
ramified, as the processes extending from the microglia body can be seen. There is no 
focal region in the tissue where these microglia appear to congregate; rather, there is a 
general increase in number observed throughout the entire tissue. This is evidence that 
the brain does sense the presence of the SIV virus and is taking initial steps to combat the 
infection. In addition, these results were constant across the majority of tissue sections 
observed. There was very little variation in trends between the two animals, or in the 
different areas of the brain that were stained for the various molecules. 
 Significant variation was observed, however, when regarding different sections of 
the brain in different macaques after the development of SIVE. Four infected animals 
were investigated in this project, A97-596, A98-41, A00-360, and A98-182. Photographs 
were taken only of the first three animals listed, primarily for the reason that the lesions 
seen in the chosen tissues were the most substantial and had the most noteworthy results. 
Instead of attempting to quantify the number of positive cells in each lesion, a task which 
would have been almost impossible to do, a percentage of positively stained cells in the 
lesion was estimated. 
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 All of the lesions observed were highly positive for SIV-p28. The three lesions in 
the hippocampus of A98-41, the sizeable lesion in the cerebrum of the same macaque, 
and the lesion in A97-596 all were SIV-p28+ in over 75% of cells. The other 
photographed lesion in A00-360 had about 50% of SIV-p28+ cells, but they were highly 
focused in three different areas of the lesion, indicating that the lesion was caused by the 
combination of macrophage accumulation to the three different sites of infection.  
 CD163 accumulation was also noticed in each of the lesions. It was very 
significant in A97-596, and as expected, was found around blood vessels. The large 
lesion in A98-41 is surrounding a blood vessel, and CD163 is positively stained in close 
to 100% of the cells. The smaller lesions in A98-41 also had almost 100% of cells 
CD163+. These lesions were not surrounding blood vessels, so the CD163+ perivascular 
macrophages had to have migrated from the blood vessels to the lesion area, or it is 
possible that the blood vessels in the region had collapsed. Also, an increase in CD163+ 
cells is observed in the entire tissue region, not just in the lesion. This may be the positive 
staining of scattered microglia that have been shown to express CD163 in late stage 
disease. Interestingly, the lesion in A00-360 had a very little amount of CD163+ cells 
relative to the other lesions. In this lesion, approximately 50% of cells within the lesion 
stained positive for the glycoprotein, and they appear to be the same cells that were 
positively stained for SIV-p28. This would indicate that these perivascular macrophages 
may have brought the virus to the area where the lesion formed. All of the cells that were 
SIV-p28+ do not appear to also be CD163+, demonstrating that the virus has also 
infected other cells in the proximate region. It is hard to determine whether all of the 
CD163+ cells are also positive for the viral protein. 
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 Each of the lesions exhibited an increase in expression for CD16. In A98-41, 
cerebrum, the lesion is darkly stained, and almost 100% of the cells are CD16+. In A98-
41, hippocampus, the lesions are also almost completely positive for the marker, and the 
intensity of staining is high. In A00-360, the lesion shows a similar staining pattern to the 
CD163 stain, with about 50% of cells CD16+, and the CD16+ cells are correspondingly 
localized within the lesion to the CD163+ cells. In A97-596, the number of CD16+ cells 
is not as substantial, and the staining is less intense. This is evidence of less of a 
monocyte population within the lesion compared to the other lesions observed. 
 The final similarity observed between each of the lesions is visible in the Iba-1 
stain. All lesions showed a dramatic increase in the expression of Iba-1 within the lesion 
area, as well as in the surrounding tissue. The lesion in A97-596 showed a definitive 
congregation of Iba-1+ cells (~40%) within the lesion. In A98-41 cerebrum, about 95% 
of the cells in the lesion are Iba-1+, and the hippocampus region also had a high amount 
of Iba-1+ cells in the ramified state. Interestingly, Iba-1 expression is not focused in all 
three of the lesions. There is focal expression in the lesion seen in Figure 8f, but the two 
lesions in Figure 8e are not clearly defined by Iba-1, as seen in other SIVE lesions. 
However, these two lesions were significantly smaller than the other lesions observed, 
which may be the cause of the discrepancy. The lesion of A00-360 also showed a very 
substantial accretion of Iba-1+ ramified cells. 
 The stains for the remaining cellular markers had a high degree of variation in 
expression from one macaque to the next. From the discrepancy in the remaining 
macrophage markers seen between the various lesions, it is possible to categorize several 
of the lesions as either “old” or “new”. “New” lesions presented with a relatively high 
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count of Mac387 macrophages, which were newly imported from the periphery into the 
tissue after the breach of the blood-brain barrier. An example of a “new” lesion would be 
one of the small lesions in the hippocampus of animal A98-41 (Figure 7g). This lesion 
had about 10% of the cells positive for Mac387. The positively stained cells vary in 
staining intensity. Two of the Mac387+ cells are darkly stained, although most are only 
stained lightly. Mac387 is obviously expressed to various degrees depending on the 
macrophage. The lesion in A98-41 cerebrum also has a high number of Mac387+ 
macrophages. Again, there is a variation in the intensity of staining between these cells. 
Interesting to note is that the most darkly stained macrophages are located on the 
periphery of the lesion, and lighter stained Mac387+ cells are seen in the more interior 
regions. The lesion in A00-360 has a lesser amount of Mac387+ cells, which are best 
seen in the double stain with HAM56 (Figure 9h). The lesion in A97-596 shows hardly 
any Mac387+ cells. 
CD68, a marker generally believed to be found on later stage macrophages, and 
HAM56, the CNS macrophage marker, can be used to categorize a lesion as “old”. The 
lesion in A97-596 that had barely any Mac387+ macrophages exhibited a significant 
amount of HAM56+ cells, approximately 30%. This lesion also had about 50% of cells 
strongly positive for CD68. The additional lack of Mac387+ macrophage indicate that 
this is an “old” lesion. The lesion in A00-360 also had a similar proportion of HAM56+ 
cells, around 40%, and the majority of cells are also CD68+. A98-41 cerebrum 
demonstrated a very strong stain for CD68, almost 100% of the cell population, as did the 
hippocampus lesions. Both tissue samples from this animal also displayed HAM56+ 
macrophages of similar abundances (~50% of cells within the lesion), with the exception 
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of the one small lesion in the hippocampus, which showed very little HAM56+ 
macrophages, although a very high number of CD68+ macrophages were expressed 
(Figure 8a,c). It was shown that CD68 and HAM56 are coexpressed within lesions 
(Figure 8h, 6b), but the evidence also shows that this is not always the case. 
If a “new” lesion is categorized by the presence of Mac387+ macrophages, then it 
is evident that an “old” lesion can be classified by its lack of Mac387, rather than the 
presence of late macrophage markers such as HAM56 and CD68. HAM56 and CD68 
were seen with great intensity in most lesions containing Mac387+ cells; therefore, it is 
clear that they are present in lesions of all ages. It can be concluded that a “new” lesion in 
SIVE is one that is still actively recruiting macrophages from the periphery, which are 
Mac387+. An “old” lesion, such as the lesion in A97-596, is no longer recruiting new 
differentiating monocytes to aid in the attack against the virus.  
This project also enabled observations of the staining patterns and intensities of 
the MNGCs present in the lesions. There were several MNGCs visible in the cerebrum 
lesion in A98-41. As previously published, the MNGCs were seen to be positive for 
CD163. Many were also clearly positive for CD68 and Iba-1, as well as the SIV-p28 
prtoein. Mac387 did not appear to stain these cells, and the staining for HAM56 was hard 
to interpret.  
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Conclusion 
 The primary focus of this project was to analyze the different macrophage 
populations in rhesus macaques infected with SIV at various stage of disease. The 
majority of time on this project was spent learning how to perform, interpret, and analyze 
immunohistochemistry stains on various brain tissues. Both double and single 
immunohistochemistry protocols were followed and yielded significant results. Other 
results were more inconclusive. 
 It is apparent that the number of macrophages increases in the brain slightly after 
the initial infection. In the animals sacrificed approximately two weeks after infection 
with SIV, there is a noticeable, if not dramatic, increase in the number of CD163+, 
CD16+, CD68+, Mac387+, and Iba-1+ cells in the tissue compared to the uninfected 
control. These increases were primarily around vessel regions, which supports the 
conclusions that the virus comes into the brain through the blood-brain barrier. There is 
very little infiltration of positively stained macrophages or monocytes within the tissue 
itself at this stage, and no lesions are present. 
 Later in disease, it is easy to observe the drastic amount of macrophage 
infiltration that has occurred, especially around lesions and perivascular cuffs. It is 
possible to draw several conclusions regarding the age of the lesion within the infected 
animal. The presence of Mac387, a marker expressed by monocytes as they differentiate 
to macrophage in the early states of recruitment to the brain, indicates that a lesion is 
“new” and actively recruiting aid in the form of uninfected macrophages from the 
peripheral blood. In these “new” lesions, a significant population of cells are later stage 
CNS macrophages, expressing CD68 and HAM56. Many are SIV-p28+, indicating viral 
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infection. The high percentage of CD16+ cells within these lesions also is suggestive of 
monocytes being recruited to the site. It is also clear that microglia are present in large 
percentages, and CD163+ perivascular cells are also organized at the site, which is 
expected if the perivascular cells are responsible for the original transportation of the 
virus.  
 A lack of Mac387 macrophages leads to the belief that the lesion is an “old” 
lesion and most likely has been existent in the brain tissue for quite some time. These 
lesions still retain a large display of CD68+ and HAM56+ macrophages, as well as cells 
positive for SIV-p28, CD163, and Iba-1. These macrophages are still active within the 
lesion, but the lack of new Mac387+ cells and CD16+ monocytes shows that no further 
mobilization was occurring at the time of sacrifice. These lesions are still significant 
sources of the virus within the brain, indicated by the SIV-p28+ cells. Another conclusion 
that can be made is that in many late stage macrophages, CD68 and HAM56 are 
coexpressed, and this could be visualized in a double immunohistochemistry stain. 
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Figure 1: Immunohistochemistry stains for A08-257, cortex (a) P28 (b) CD163 (c) CD16 (d) 
Mac387 (e) HAM56 (f) CD68 (g) Iba1 (h) CD68/Mac387 
(a) (b) 
(c) (d) 
(e) (f) 
(g) (h) 
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Figure 2: Immunohistochemistry stains for A01-250,  temporal cortex (a) P28 (b) CD163 (c) 
CD16 (d) Mac387 (e) HAM56 (f), (g) CD68 
(a) (b) 
(c) (d) 
(e) (f) 
(g) 
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Figure 3: Immunohistochemistry stains for A01-256,  parietal cortex (a) P28 (b) CD163 (c) 
CD16 (d) Mac387 (e) HAM56 (f) CD68 (g) Iba1 (h) CD68/Mac387 
(a) (b) 
(c) (d) 
(e) (f) 
(g) (h) 
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Figure 4: Immunohistochemistry stains for A97-596, temporal and hippocampus. (a) P28 (b) 
Glut1/CD163 (c) CD16 (d) Mac387 (e) HAM56 (f) CD68 (g) Iba1 (h) HAM56/Mac387 
(a) (b) 
(c) (d) 
(e) (f) 
(g) (h) 
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Figure 5: Immunohistochemistry stains for A98-41,  cerebrum (a) P28 (b) CD163 (c) CD16 (d) 
Mac387 (e) HAM56 (f) CD68 (g) Iba1 (h) CD68/Mac387 
(a) (b) 
(c) (d) 
(e) (f) 
(g) (h) 
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Figure 6: Immunohistochemistry stains for A98-41,  cerebrum (a) CD68 (b) HAM56/CD68  
(a) (b) 
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Figure 7: Immunohistochemistry stains for A98-41, hippocampus (a), (b) P28 (c), (d) CD163 
(e), (f) CD16 (g), (h) Mac387 
(a) (b) 
(c) (d) 
(e) (f) 
(g) (h) 
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Figure 8: Immunohistochemistry stains for A98-41,  hippocampus (a), (b) HAM56 (c), (d) CD68 
(e), (f) Iba1 (g) CD68/Mac387 (h) HAM56/CD68 
(a) (b) 
(c) (d) 
(e) (f) 
(g) (h) 
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Figure 9: Immunohistochemistry stains for A00-360, occipital cortex. (a) P28 (b) CD163 (c) 
CD16 (d) Mac387 (e) HAM56 (f) CD68 (g) Iba1 (h) HAM56/Mac387 
(a) (b) 
(c) (d) 
(e) (f) 
(g) (h) 
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